Andean highlanders adapt to thin air through epigenetic gene tuning, revealing a flexible, long-term path to altitude survival.
A placebo-controlled trial has shown that the oral AKT inhibitor engasertib could reduce the frequency and duration of ...
Ipatasertib showed significant activity in patients with AKT1E17K mutations, with a 24.1% objective response rate and a median response duration of 10.1 months. The trial's 6-month progression-free ...
DNA sequencing technology makes it possible to explore the genome to learn how humans adapted to live in a wide range of ...
An aggressive breast cancer lacking common drug targets, triple-negative breast cancer may be countered by oridonin, a ...
Lung cancer remains the most frequently diagnosed malignancy and the leading cause of cancer tumour-related mortality ...
A team of researchers from the Germans Trias i Pujol Research Institute (IGTP) and Institut Català d'Oncologia (ICO) has ...
A clinical trial of Vaderis Therapeutics' AKT inhibitor engasertib suggests it could be the first effective treatment for ...
Circadian rhythms are endogenous oscillations widely present in living organisms, typically following approximately 24-hour ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback